Jackie Oden, APRN
Women's Health · Lincoln, NENPI 1427043397
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 27.4% of the total. Reporting peaked in 2022 at $946 and has fallen 74.3% since, to $243 in 2025.
Across 128 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$779
- Astellas Pharma US Inc$569
- Biohaven Pharmaceutical Holding Company Ltd.$263
- Mayne Pharma Commercial LLC$171
- Boston Scientific$149
- Pfizer$109
- plus $801 from 18 others
What the payments were for
- Food & beverage$2,842100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $779 |
| Astellas Pharma US Inc | 21 | $569 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $263 |
| Mayne Pharma Commercial LLC | 14 | $171 |
| Boston Scientific | 1 | $149 |
| Pfizer | 6 | $109 |
| Bayer | 5 | $91 |
| Idorsia Pharmaceuticals US Inc | 2 | $78 |
| Agile Therapeutics, Inc. | 5 | $75 |
| Organon | 3 | $61 |
| Novo Nordisk | 1 | $58 |
| Sumitomo Pharma America, Inc. | 4 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $52 |
| Myovant Sciences Inc. | 4 | $52 |
| Janssen Scientific Affairs, LLC | 1 | $51 |
| Therapeuticsmd, Inc. | 2 | $36 |
| Avion Pharmaceuticals | 2 | $35 |
| Lilly USA, LLC | 2 | $27 |
| Exeltis, USA Inc. | 2 | $26 |
| BD | 1 | $25 |
| Gynesonics, Inc. | 1 | $24 |
| Merck | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$149
- QULIPTA$125
- UBRELVY$125
How this compares
$2,842 in reported general payments places this provider in the 85th percentile of 60 women's health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 51 | $2,119 |
| DottiEstradiol | 23 | $1,586 |
| ProgesteroneProgesterone, Micronized | 16 | $395 |
| Escitalopram Oxalate | 13 | $153 |
| Levothyroxine Sodium | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Other women's health in Lincoln
- Allison WhiteLincoln$3K
- Terra VejraskaLincoln$3K
- Audrey GrayLincoln$2K
- Jodi WegnerLincoln$2K
- Elizabeth HanselingLincoln$2K
- Lindsey MaasLincoln$1K
- Kathleen HunleyLincoln$1K
- Paula RailsbackLincoln$1K
- Mary SnowLincoln$944
- Emilie LongLincoln$937
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.